Skip to content
Peptide research

Triptorelin

Also known as Trelstar · Decapeptyl
Category
Hormone & Sexual Health
Administration routes
Injectable
Regulatory status
FDA-approved

A synthetic GnRH agonist that suppresses testosterone or estrogen to castrate levels after an initial hormone surge. Human evidence is strong: it is an established treatment for advanced prostate cancer, endometriosis, precocious puberty, and IVF ovarian suppression. Real risks include the initial tumor flare, meaningful bone density loss, hot flashes, and sexual dysfunction. It is an FDA-approved prescription drug, not a longevity or wellness product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Trelstar and Triptodur (triptorelin) is a synthetic 10-amino-acid hormone medication that acts on the pituitary gland to control the body's production of sex hormones. Initially, it briefly stimulates hormone production, but with continued use it shuts down the hormone signal entirely, reducing testosterone or estrogen to very low levels. It is FDA-approved for advanced prostate cancer (Trelstar) and early puberty in children (Triptodur), and is widely used internationally for endometriosis, uterine fibroids, and IVF protocols.

How it works in the body

A GnRH agonist that initially causes a surge of LH and FSH from the pituitary (flare effect). With continuous administration, it desensitizes pituitary GnRH receptors, causing LH and FSH to drop to castration levels. This suppresses testosterone/estrogen production — used for prostate cancer and endometriosis.

Research overview

Triptorelin has one of the most extensive evidence bases of any peptide therapeutic, backed by decades of large randomized controlled trials. It works through a two-phase mechanism: first a brief hormone surge (the 'flare'), then sustained suppression by overwhelming and desensitizing pituitary receptors. The landmark EORTC trial (1,113 registered; 970 randomized patients) established that long-term triptorelin with radiation therapy provides a significant survival benefit in prostate cancer. In endometriosis, a controlled trial showed 50% reduction in lesion size versus worsening with placebo. In children with early puberty, studies show 87-100% suppression of puberty hormones to prepubertal levels. Side effects are directly related to its intended hormone-suppressing action: hot flashes, bone density loss, sexual dysfunction, and metabolic changes. The overall benefit-risk profile is well established across all approved uses.

Who researches Triptorelin?

Commonly researched by

  • People researching effective androgen deprivation in advanced prostate cancer

    One of the primary studied benefits of Triptorelin.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    FDA contraindication. Can cause fetal harm and spontaneous abortion.

  • Those with Osteoporosis (severe)

    High

    Long-term use causes bone density loss through sex hormone suppression.

  • Those with Undiagnosed vaginal bleeding

    Absolute

    Must rule out malignancy before starting GnRH agonist therapy.

Safety & interactions

Do not use if

  • Undiagnosed vaginal bleeding

    Absolute

    Must rule out malignancy before starting GnRH agonist therapy.

  • Osteoporosis (severe)

    High

    Long-term use causes bone density loss through sex hormone suppression.

General cautions

  • Pregnancy

    Absolute

    FDA contraindication. Can cause fetal harm and spontaneous abortion.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(9)

Rated by level of concern

  • Tumor flare (initial hormone surge)

    High

    Trelstar label Warnings & Precautions (Tumor Flare); TRIPTODUR label ('Initial Rise of Gonadotropins and Sex Steroid Levels')

  • Cardiovascular events (MI, stroke, sudden cardiac death)

    Moderate

    Trelstar label (Cardiovascular Disease); PMID 24210090 (Eur Urol 2014); PMID 41103953 (Front Oncol 2025 meta-analysis); PMID 39801649 (JACC CardioOncol 2024 review)

  • QT prolongation and torsade de pointes

    Low

    Trelstar label (QT/QTc Prolongation); PMID 29761176 (J Endocr Soc 2018); PMID 36895314

  • Bone mineral density loss and fracture risk

    High

    PMID 33577365 (J Urol 2021); PMID 19671656 (NEJM 2009, denosumab in men on ADT - fracture reduction confirms the underlying risk)

  • Metabolic effects (hyperglycemia, diabetes, dyslipidemia)

    Moderate

    Trelstar label (Metabolic Syndrome / Hyperglycemia and Diabetes)

  • Hot flashes and vasomotor symptoms

    High

    Trelstar label, Adverse Reactions

  • Sexual dysfunction and loss of libido

    High

    Trelstar label, Adverse Reactions (Impotence 7.1%, Erectile Dysfunction 10.0%)

  • Seizures and neuropsychiatric effects

    Low

    Trelstar label (Convulsions); TRIPTODUR label (Convulsions, Psychiatric Events, Pseudotumor Cerebri)

  • Pregnancy exposure (teratogenicity)

    High

    Trelstar label (Embryo-Fetal Toxicity); Use in Specific Populations - Pregnancy

Interaction summary(8)

Rated by direction with this peptide

  • Hyperprolactinemic drugs (antipsychotics, metoclopramide, domperidone)

    CautionModerate

    Both triptorelin labels state these should be avoided concomitantly because hyperprolactinemia reduces the number of pituitary GnRH receptors, which can blunt the intended pituitary response.

    Trelstar and TRIPTODUR labels, Drug Interactions (DailyMed)

  • Antiandrogens (bicalutamide, flutamide, nilutamide)

    ProtectiveModerate

    Starting an antiandrogen before or with the first triptorelin dose blunts the clinical consequences of the initial testosterone surge and is standard practice in men with high tumor burden or impending cord compression/urinary obstruction.

    Trelstar label (Tumor Flare); standard ADT flare-prophylaxis practice

  • Bone-protective agents (denosumab, zoledronic acid, calcium/vitamin D)

    ProtectiveHigh

    Randomized data in men on androgen deprivation show denosumab increases bone mineral density and reduces new vertebral fractures, directly offsetting the most consequential long-term harm of triptorelin.

    PMID 19671656 (NEJM 2009); PMID 33577365

  • Hormonal add-back therapy (norethindrone acetate +/- low-dose estrogen) in women

    ProtectiveModerate

    Randomized evidence in women on GnRH agonists for endometriosis shows add-back preserves bone density and reduces vasomotor symptoms without abolishing pain benefit, enabling longer treatment courses.

    PMID 26181088 (Obstet Gynecol 2015); PMID 15730171

  • Other QT-prolonging drugs (class IA/III antiarrhythmics, methadone, moxifloxacin, some antipsychotics and antiemetics)

    CautionModerate

    Androgen deprivation itself prolongs QTc, so the label advises weighing benefit against risk in patients on other QT-prolonging agents or with electrolyte abnormalities; the interaction is additive/pharmacodynamic, not metabolic.

    Trelstar label (QT/QTc Prolongation); PMID 29761176

  • Insulin and oral antihyperglycemic agents

    CautionLow

    Not a documented drug-drug interaction but a metabolic consequence: triptorelin-induced insulin resistance and hyperglycemia develop over months and can degrade glycemic control, so the label recommends periodic glucose (or HbA1c) monitoring and antidiabetic therapy may need adjustment. This is a slow metabolic drift, not a co-administration hazard.

    Trelstar label (Hyperglycemia and Diabetes)

  • Testosterone or estrogen replacement / anabolic androgens

    CautionModerate

    Exogenous sex steroids directly oppose the therapeutic goal of triptorelin (castrate hormone levels) and can invalidate testosterone-based monitoring of treatment adequacy. This is a mechanistic/pharmacodynamic antagonism rather than a documented formal DDI.

    Mechanistic; Trelstar label monitoring guidance (serum testosterone/PSA)

  • CYP450-metabolized drugs generally

    NeutralLow

    Triptorelin is a decapeptide cleared by peptidases rather than hepatic CYP enzymes, and in vitro studies cited in the label indicate pharmacokinetic drug-drug interactions are unlikely; no formal DDI studies have been conducted.

    TRIPTODUR label, Drug Interactions ('drug-drug interactions with triptorelin are unlikely')

Known risks(9)

  • Tumor flare (initial hormone surge)

    High (potentially life-threatening in metastatic prostate cancer)

    During the first 1-2 weeks of treatment, triptorelin causes a transient surge in testosterone (in men) or estradiol (in women) before suppression occurs. In prostate cancer patients with bone metastases, this flare can cause severe bone pain, spinal cord compression, and urinary obstruction — potentially constituting a medical emergency. Managed with concurrent antiandrogen therapy (flutamide, bicalutamide) for the first 2-4 weeks. FDA black box warning.

  • Cardiovascular events (MI, stroke, sudden cardiac death)

    High

    Androgen deprivation therapy with triptorelin increases cardiovascular risk. This includes increased risk of myocardial infarction, stroke, and sudden cardiac death, with higher risk in patients with pre-existing cardiovascular disease and with longer duration of therapy. Mechanisms include adverse metabolic effects (weight gain, insulin resistance, dyslipidemia), increased arterial stiffness, and endothelial dysfunction. Baseline cardiovascular risk assessment and ongoing monitoring are recommended.

  • QT prolongation and torsade de pointes

    High (rare but potentially fatal)

    Triptorelin may cause QT interval prolongation, which can lead to the potentially fatal arrhythmia torsade de pointes. Risk is increased when triptorelin is combined with other QT-prolonging medications (certain antiarrhythmics, fluoroquinolone antibiotics, macrolide antibiotics, antipsychotics, certain antidepressants). Baseline and periodic ECG monitoring may be appropriate. Electrolyte imbalances (hypokalemia, hypomagnesemia) should be corrected before treatment.

  • Bone mineral density loss and fracture risk

    Moderate to High (with long-term use)

    Long-term triptorelin therapy causes progressive bone density loss due to sustained sex hormone suppression. BMD can decrease 2-5% per year during ADT. Risk factors include older age, pre-existing osteopenia or osteoporosis, family history, and concurrent use of corticosteroids or anticonvulsants. Periodic DEXA scans, calcium/vitamin D supplementation, weight-bearing exercise, and consideration of bone-protective agents (bisphosphonates, denosumab) are recommended for patients on long-term therapy.

  • Metabolic effects (hyperglycemia, diabetes, dyslipidemia)

    Moderate

    Triptorelin-induced androgen deprivation increases blood glucose levels and risk of developing diabetes mellitus. It also causes dyslipidemia (elevated triglycerides and cholesterol) and weight gain. These metabolic changes may be asymptomatic initially but increase long-term cardiovascular risk. Monitoring of fasting glucose, HbA1c, and lipid panels is recommended, particularly in patients with pre-existing metabolic risk factors.

  • Hot flashes and vasomotor symptoms

    Low to Moderate (quality of life impact)

    Hot flashes are the most common side effect, occurring in 60-80% of patients on triptorelin ADT and 80% of women treated for endometriosis. While not dangerous, they significantly affect quality of life. Other vasomotor symptoms include night sweats, fatigue, and mood changes. Management options include venlafaxine, gabapentin, or medroxyprogesterone.

  • Sexual dysfunction and loss of libido

    Moderate (expected pharmacological effect)

    Testosterone suppression to castrate levels causes erectile dysfunction, decreased libido, and reduced sexual function in virtually all male patients. In women treated for endometriosis, hypoestrogenic effects reduce vaginal lubrication and libido. These effects are generally reversible upon discontinuation of therapy but may persist for weeks to months.

  • Seizures and neuropsychiatric effects

    Moderate (rare)

    Post-marketing reports include seizures, depression, mood changes, and emotional lability. Patients with a history of seizure disorder, cerebrovascular disease, or CNS pathology may be at increased risk. New or worsening mental health symptoms should be reported to the prescribing physician.

  • Pregnancy exposure (teratogenicity)

    High (contraindicated)

    Triptorelin is contraindicated in pregnancy (FDA Pregnancy Category X). It may cause fetal harm including spontaneous abortion and fetal abnormalities. Women of reproductive potential must use effective nonhormonal contraception during treatment and should be tested for pregnancy before initiating therapy.

Drug interactions(5)

  • QT-prolonging medications (antiarrhythmics, fluoroquinolones, macrolides, antipsychotics)

    Triptorelin may cause QT prolongation and should be used with caution in patients receiving other drugs known to prolong the QT interval. These include Class IA antiarrhythmics (quinidine, procainamide), Class III antiarrhythmics (amiodarone, sotalol), fluoroquinolone antibiotics (moxifloxacin, levofloxacin), macrolide antibiotics (erythromycin, azithromycin), antipsychotics (haloperidol, ziprasidone), and certain antidepressants (citalopram). Concurrent use increases the risk of torsade de pointes. ECG monitoring is recommended.

  • Hyperprolactinemic drugs (metoclopramide, antipsychotics, risperidone)

    Drugs that cause hyperprolactinemia should not be used concomitantly with triptorelin because hyperprolactinemia reduces the number of pituitary GnRH receptors, potentially diminishing triptorelin's efficacy. This is the only pharmacodynamic drug interaction specifically noted in the FDA prescribing information.

  • Antiandrogens (flutamide, bicalutamide, enzalutamide)

    Antiandrogens are intentionally co-administered with triptorelin during the first 2-4 weeks of therapy to counteract the initial testosterone flare. This is a beneficial and expected drug interaction. In combined androgen blockade (CAB) protocols, continuous antiandrogen therapy alongside triptorelin may provide additional benefit. Not a contraindicated interaction — it is standard clinical practice.

  • Diabetes medications (insulin, metformin, sulfonylureas)

    Triptorelin-induced androgen deprivation can increase blood glucose levels and reduce insulin sensitivity, potentially requiring dosage adjustments of diabetes medications. Patients with pre-existing diabetes should have more frequent glucose monitoring when starting triptorelin. New-onset diabetes has been reported during triptorelin ADT.

  • Bone-active drugs (bisphosphonates, denosumab, calcium/vitamin D)

    These agents are often intentionally co-prescribed with long-term triptorelin therapy to counteract bone mineral density loss. Zoledronic acid or denosumab may be recommended for patients on extended ADT. This is a beneficial co-administration, not a contraindicated interaction. Calcium and vitamin D supplementation is standard supportive care.

Research & benefits

Evidence base

Evidence Level
Level 1 — FDA Approved
Total Studies
200
Human Studies
150

Triptorelin has one of the strongest evidence bases among peptide therapeutics, with Level I evidence across its primary indications. In prostate cancer, the EORTC 22961 trial (1,113 registered; 970 randomized; published in NEJM) is the cornerstone study demonstrating survival benefit for long-term ADT with triptorelin. This is supported by multiple Phase III trials demonstrating consistent testosterone suppression, a multicenter RCT confirming equivalence to surgical castration, and large-scale pharmacovigilance data from decades of post-marketing use. In endometriosis, the Bergqvist 1998 double-blind placebo-controlled RCT provides Level I evidence for lesion reduction and symptom control. In CPP, multiple Phase III trials and a meta-analysis support triptorelin's efficacy in achieving prepubertal hormone suppression. In IVF, triptorelin is an established standard-of-care agent for pituitary downregulation, supported by numerous RCTs. Safety is well-characterized through decades of clinical experience and FAERS pharmacovigilance analysis. Overall, triptorelin's evidence base is mature and robust — it is not an experimental peptide but a well-established pharmaceutical.

Researched for(5)

Rated by confidence in the evidence

  • Effective androgen deprivation in advanced prostate cancer

    High

    FDA-approved; randomized trial showed non-inferiority to leuprolide, backed by Cochrane review.

    PMID 12887472 (Heyns et al., BJU Int 2003); PMID 24979481 (Cochrane Database Syst Rev 2014); Trelstar label, DailyMed setid b1b84d62-a369-a4b7-5c41-dd1f553a18f3

  • Reduction of endometriotic lesions and pain symptoms

    High

    Placebo-controlled and post-surgical randomized trials show reduced pelvic pain and lesion severity.

    PMID 9548161 (Fertil Steril 1998, triptorelin vs placebo); PMID 17178185 (Eur J Obstet Gynecol Reprod Biol 2008, randomized post-laparoscopy)

  • Suppression of precocious puberty in children

    Medium

    Open-label pediatric trials show hormone suppression; no placebo-controlled study exists for ethical reasons.

    TRIPTODUR label, DailyMed setid f41380e7-b830-432d-a5f5-a872932f107e; PMID 26887034 (J Pediatr Endocrinol Metab 2016)

  • Pituitary downregulation for IVF and assisted reproduction

    High

    Multiple randomized IVF trials confirm suppression of LH surge; live-birth superiority over antagonists unproven.

    PMID 26558801 (Cochrane Database Syst Rev 2015, GnRH agonist protocols for pituitary suppression in ART)

  • Achievement and maintenance of castrate testosterone levels

    High

    Phase III human trials confirm castrate testosterone by week four, sustained through the dosing interval.

    PMID 12887472 (randomized vs leuprolide); PMID 19888782 (Clin Drug Investig 2009, phase III 6-month formulation); Trelstar label

Benefits(5)

  • Effective androgen deprivation in advanced prostate cancer

    EORTC 22961 (Bolla et al. NEJM 2009, PMID 19516032) — landmark trial with 1,113 registered and 970 randomized men with locally advanced prostate cancer demonstrating that long-term triptorelin-based ADT (36 months) combined with radiotherapy provides significant overall survival benefit over short-term ADT (6 months). Botto et al. 2007 (PMID 17489325) — RCT of 80 patients demonstrating equivalent survival between monthly triptorelin and surgical castration (median survival 37.5 vs 33 months). Klotz and Tat 2024 (PMID 38481666) — pooled analysis of 592 patients from three Phase III trials reporting an association between lower testosterone nadir and improved overall survival.

  • Reduction of endometriotic lesions and pain symptoms

    Bergqvist et al. 1998 (Fertil Steril, PMID 9548161) — double-blind RCT of 49 women showing triptorelin reduced endometriotic lesion extent by 50% (vs 17% increase with placebo), reduced lesion area by 45%, and significantly reduced pain symptoms within 2 months. Porpora et al. 2007 (PMID 17178185) — RCT comparing post-surgical triptorelin to expectant management in stage III-IV endometriosis.

  • Suppression of precocious puberty in children

    Carel et al. 2006 (PMID 16382000) — multicenter open-label trial in 64 CPP children treated with triptorelin 11.25 mg quarterly demonstrating GnRH-stimulated peak LH suppression in 85% at 3 months and 97% at 6 months. Carel et al. 2017 (PMID 28334719) — meta-analysis of 153 pediatric CPP patients showing 87.6% LH suppression at 3 months. Phase 3 Chinese trial (2023, PMID 37584898) — 100% LH suppression at 3 months in 31 children with CPP.

  • Pituitary downregulation for IVF and assisted reproduction

    Ron-El et al. 2001 (PMID 11425821) — RCT demonstrating that reduced-dose triptorelin (50 mcg/day) was equivalent to 100 mcg/day for pituitary suppression during IVF, and that as little as 15 mcg/day prevented premature LH surge. Triptorelin (as Decapeptyl) is widely used in IVF long protocols for controlled ovarian stimulation, enabling scheduled egg retrieval.

  • Achievement and maintenance of castrate testosterone levels

    Phase III pivotal studies — castrate testosterone levels (<50 ng/dL) achieved in 91.2% of patients by Day 29 and 97.7% by Day 57 with Trelstar 3.75 mg monthly. Schroeder et al. 2017 (PMID 27939836) — RCT demonstrating that LHRH agonists (including triptorelin) are superior to subcapsular orchiectomy in achieving lower testosterone nadir levels.

Key studies(5)

  1. Duration of Androgen Suppression in the Treatment of Prostate Cancer

    Randomized controlled trial (Phase III)1,113 men registered; 970 randomized, including 483 assigned to short-term and 487 to long-term suppressionShort-term (6 months) vs long-term (36 months) triptorelin-based ADT + radiotherapy

    Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group

    New England Journal of Medicine

    2009

    Landmark EORTC 22961 trial. Long-term androgen suppression with triptorelin (36 months) combined with radiotherapy significantly improved overall survival compared to short-term suppression (6 months) in locally advanced prostate cancer. Five-year overall mortality was 15.2% in the long-term arm versus 19.0% in the short-term arm, establishing that extended triptorelin ADT provides a survival benefit for this patient population. This trial was pivotal in defining the optimal duration of ADT in combination with radiation.

  2. Effects of triptorelin versus placebo on the symptoms of endometriosis

    Randomized, double-blind, placebo-controlled trial49 women with laparoscopically verified endometriosis6 months treatment, 12 months follow-up

    Bergqvist A, Bergh T, Hogstrom L, Mattsson S, Nordenskjold F, Rasmussen C

    Fertility and Sterility

    1998

    First rigorous placebo-controlled trial of triptorelin for endometriosis. Pain symptoms were significantly reduced within 2 months of triptorelin treatment versus placebo. Endometriotic lesion extent was reduced by 50% during triptorelin treatment versus a 17% increase during placebo. Average lesion area decreased 45% with triptorelin versus unchanged with placebo. Side effects (mainly hot flushes) occurred in 80% of the triptorelin group and 33% of placebo. Established triptorelin as an effective medical therapy for endometriosis.

  3. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty

    Multicenter, open-label Phase III trial64 children with CPP (54 girls, 10 boys)12 months quarterly injections

    Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N; Triptorelin 3-Month CPP Study Group

    European Journal of Endocrinology

    2006

    Demonstrated efficacy of the 3-month sustained-release triptorelin formulation for CPP. GnRH-stimulated peak LH was suppressed to prepubertal levels (<=3 IU/L) in 85% of children at 3 months, 97% at 6 months, and 95% at 12 months. Bone age progression was slowed. The treatment was well tolerated with injection-site reactions being the most common adverse event. Established the quarterly 11.25 mg formulation as effective for sustained pubertal suppression.

  4. Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies

    Post hoc pooled analysis of three Phase III trials592 patients with advanced prostate cancer9-12 months per study

    Klotz L, Tat T

    BJUI Compass

    2024

    Pooled analysis of three prospective Phase III triptorelin monotherapy studies. Lower testosterone nadir achieved during triptorelin treatment was significantly associated with improved overall survival and disease-specific survival. Patients achieving deeper testosterone suppression had better clinical outcomes, supporting the concept that the degree of testosterone suppression matters and that triptorelin can achieve very low nadir levels.

  5. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

    Comprehensive clinical reviewReview of all major triptorelin clinical trialsN/A (review article)

    Merseburger AS, Hupe MC

    Advances in Therapy

    2016

    Comprehensive review establishing triptorelin as a first-line hormonal therapy for advanced prostate cancer with demonstrated efficacy and safety across all formulations (monthly, quarterly, 6-month depot). The review confirmed that triptorelin achieves castrate testosterone levels in >95% of patients, provides subjective symptom improvement and objective disease responses, and has a safety profile consistent with the GnRH agonist class.

What research suggests over time

  • Weeks 2-4

    FDA labeling

    Initial 'flare' rise in LH/FSH and testosterone (1-2 weeks), then receptor downregulation begins; clinicians often co-prescribe an anti-androgen to cover the flare.

  • Months 2-3

    Phase 3 RCT

    Castrate testosterone levels achieved in prostate cancer patients; PSA decline; menstrual suppression in endometriosis.

  • Long-term

    Phase 3 (EORTC)

    Combined with radiotherapy, 36-month adjuvant triptorelin significantly improved overall survival in locally advanced prostate cancer (EORTC 22961, NEJM 2009; 1,113 registered, 970 randomized).

Prescribing labels

FDA-Approved Labels

This page does not list doses. Each product below has an FDA label with its prescribing information.

Protocol
Trelstar (triptorelin pamoate)
Notes
Dosing is set by your prescriber and the FDA label.
Protocol
Triptodur (triptorelin)
Notes
Dosing is set by your prescriber and the FDA label.

Monitoring & labs

Baseline before starting, then per marker schedule during protocol.

Baseline labs(6)

  • Complete Blood Count (CBC)

    Optimal All markers within mid-range

    Establishes baseline for detecting hematological changes.

    Lab normal Standard reference ranges

  • Comprehensive Metabolic Panel (CMP)

    Optimal Liver enzymes <25, glucose 75–90, eGFR >90

    Liver and kidney function baseline.

    Lab normal Standard reference ranges

  • Hormone panel (testosterone, estradiol, LH, FSH)

    Optimal 600–900 ng/dL (men)

    Baseline hormone levels to track peptide effects.

    Lab normal 264–916 ng/dL (men)

  • Prolactin

    Optimal Under 12 ng/mL

    Some peptides affect prolactin; baseline needed.

    Lab normal 4–15 ng/mL (men)

  • PSA (prostate-specific antigen)

    Optimal Age-adjusted; trend matters more than absolute

    Baseline prostate marker — standard before initiating therapies affecting the HPG axis.

    Lab normal Under 4.0 ng/mL

  • ECG recommended

    Baseline cardiac rhythm assessment — QT prolongation risk documented.

Ongoing tracking(3)

  • Hormone panel

    Every 6-8 weeks

    Track hormone level changes during protocol.

  • Liver enzymes (ALT/AST)

    Every 8 weeksOptimal ALT & AST under 25 U/L

    Hepatic function monitoring.

    Lab normal ALT 7–56, AST 10–40 U/L

  • Prolactin

    Every 8 weeksOptimal Under 12 ng/mL

    Monitor for prolactin-related side effects.

    Lab normal 4–15 ng/mL (men)

Retest schedule(5)

  1. Baseline

    critical

    Before starting

    Full baseline panel — establish reference values for all monitored markers.

  2. Early follow-up

    critical

    Week 4-6

    Spot-check for early changes — focus on glucose, liver enzymes, and any peptide-specific markers.

  3. Mid-protocol

    critical

    Week 12

    Comprehensive retest. Compare all markers to baseline.

  4. Ongoing

    standard

    Quarterly

    Continued monitoring during extended protocols.

  5. Post-protocol

    standard

    4-6 weeks after stopping

    Confirm return to baseline. Important for GH and metabolic peptides.

When to stop and reassess(5)

  • ALT or AST

    stop

    Above 2× upper limit of normal (>~80 U/L)

    Stop protocol and consult a provider — possible drug-induced liver injury.

  • eGFR

    stop

    Drop of >15 mL/min/1.73m² from baseline, or below 60

    Stop protocol and consult a provider — possible kidney function decline.

  • Symptoms

    stop

    New severe symptoms correlating with lab changes

    Stop protocol and seek medical evaluation immediately.

  • Prolactin

    consult

    Above 25 ng/mL

    Consult an endocrinologist — possible prolactinoma or peptide effect.

  • PSA

    consult

    Velocity >0.75 ng/mL/year or new elevation

    Consult a urologist — rising PSA warrants evaluation.

Lab monitoring helps track your body's response to Triptorelin. Any unexplained changes should prompt discussion with your prescribing provider.

Regulation & availability

Why researchers look at it

The landmark EORTC trial, which registered 1,113 men and randomized 970, established that long-term triptorelin with radiation provides a significant survival benefit in prostate cancer, and it remains a cornerstone of GnRH-based therapy worldwide. Its precise control over the HPG axis — the master regulator of sex hormones — also makes it a key research tool for understanding how hormonal shifts drive aging, bone loss, and cancer risk. Ongoing work on optimized dosing and combination regimens continues to expand its role in both oncology and reproductive medicine.

Estimated cost
$500-1,500/mo retail (Trelstar); covered by insurance for approved indications
FDA status
FDA-APPROVED. Triptorelin has two distinct FDA approvals under different brand names. Trelstar (triptorelin pamoate for injectable suspension) was approved June 15, 2000 (NDA 020715) for the palliative treatment of advanced prostate cancer. Three formulations are approved: 1-month (approved 2000), 3-month (approved June 29, 2001, NDA 021288) and 6-month (approved March 10, 2010, NDA 022437), all administered as intramuscular depot injections. Trelstar was manufactured originally by Watson Pharmaceuticals (now Allergan/AbbVie). Triptodur (triptorelin for extended-release injectable suspension) was approved June 29, 2017 (NDA 208956) for the treatment of central precocious puberty (CPP) in pediatric patients 2 years of age and older, as a 6-month intramuscular depot injection. It is marketed by Arbor Pharmaceuticals (developed by Debiopharm International). Trelstar's FDA label warns about tumor flare in prostate cancer patients during the initial treatment period; this is not a boxed warning. Additional warnings include cardiovascular risk (MI, stroke, sudden death), QT prolongation, bone density loss, hyperglycemia, and convulsions. The FDA has also issued guidance on developing GnRH analogs for advanced prostate cancer (2020).
WADA status
PROHIBITED — Males only. Triptorelin is explicitly listed by name on the WADA Prohibited List under Section S2.2.1 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics — specifically as a testosterone-stimulating peptide (formerly categorized as a GnRH agonist analog). Triptorelin is prohibited at all times (in-competition and out-of-competition) in males. The prohibition is based on triptorelin's ability to cause an initial transient surge in testosterone (the flare effect), which could theoretically be exploited for short-term performance enhancement. Other GnRH agonists on the same list include buserelin, deslorelin, goserelin, histrelin, leuprorelin, and nafarelin. Female athletes requiring triptorelin for legitimate medical indications (endometriosis, IVF) may use it but should verify their sport's specific rules. Male athletes with prostate cancer requiring triptorelin may apply for a Therapeutic Use Exemption (TUE). Athletes should verify current status through GlobalDRO.com.
Prescribability
Triptorelin is a prescription-only medication in all jurisdictions where it is approved. In the United States, Trelstar (triptorelin pamoate) is FDA-approved and available by prescription for the palliative treatment of advanced prostate cancer, administered as an intramuscular (IM) depot injection by a healthcare professional. Triptodur (triptorelin) is FDA-approved for central precocious puberty in children aged 2+ years. Both formulations require administration by or under the supervision of a physician. Outside the US, triptorelin is prescribable for additional indications including endometriosis, uterine fibroids, and as part of IVF protocols, depending on the regulatory authority. In the UK and some EU countries, triptorelin (as Salvacyl or Decapeptyl) may also be prescribed for certain behavioral indications. Triptorelin is NOT available over the counter and is not a compounding pharmacy peptide — it is a commercially manufactured pharmaceutical product available through standard prescription channels and specialty pharmacies.
Availability
Triptorelin is widely available as a commercially manufactured prescription pharmaceutical. In the United States it is available by prescription as Trelstar (triptorelin pamoate), an intramuscular depot injection in 1-month, 3-month and 6-month formulations, and as Triptodur (a 6-month depot) for CPP. No generic version is currently available in the US. It is distributed through specialty pharmacies and oncology/urology clinics. Cost without insurance is approximately $945 for the 1-month formulation, $2,819 for the 3-month, and $21,788 for the Triptodur 6-month formulation. In Europe it is available as Decapeptyl (Ipsen) for prostate cancer, endometriosis, uterine fibroids, and CPP; as Gonapeptyl (Ferring) for reproductive medicine; as Diphereline; and as Salvacyl in the UK and Germany for additional indications. It is approved across EU countries. Internationally it is marketed in over 80 countries under various brand names, including Canada, Australia, China, Japan, and most developed markets; brand names vary by country (Variopeptyl in Iran, among others). All formulations require a physician's prescription and are typically administered in a clinical setting (oncology clinic, endocrinology practice, fertility clinic).

International status

  • EU

    Nationally authorised products include Decapeptyl.

  • UK

    MHRA-approved

  • US

    FDA-approved (Trelstar)

  • Canada

    Health Canada-approved

  • Australia

    TGA-approved

Regulatory timeline(12)

  1. 1975
    Triptorelin patented by Andrew Schally and colleagues as a synthetic GnRH analog with D-Trp6 substitution, building on the 1971 Nobel Prize-winning characterization of GnRH structure.
  2. 1986
    Triptorelin first registered in France by Ipsen as Decapeptyl for treatment of prostate cancer. Subsequently approved across European and international markets.
  3. 1990s
    Regulatory approvals expand internationally. Decapeptyl approved in over 60 countries for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. Ipsen and Ferring Pharmaceuticals market under various brand names (Decapeptyl, Diphereline, Gonapeptyl).
  4. 1998-04
    Bergqvist et al. publish landmark double-blind placebo-controlled trial of triptorelin for endometriosis in Fertility and Sterility (PMID 9548161), demonstrating 50% lesion reduction vs placebo.
  5. 2000-06-15
    FDA approves Trelstar Depot (triptorelin pamoate 3.75 mg, 1-month IM depot injection, NDA 020715) for palliative treatment of advanced prostate cancer. First US approval of triptorelin.
  6. 2001-06-29
    FDA approves Trelstar LA (triptorelin pamoate 11.25 mg, 3-month IM depot injection, NDA 021288) for advanced prostate cancer, providing a longer-acting formulation.
  7. 2006
    Carel et al. publish Phase III trial of triptorelin 11.25 mg quarterly in 64 children with CPP (European Journal of Endocrinology, PMID 16382000), establishing efficacy of the 3-month formulation in pediatric patients.
  8. 2009-06-11
    Bolla et al. publish EORTC 22961 results in NEJM (PMID 19516032): landmark trial with 1,113 registered and 970 randomized patients establishing survival benefit of long-term triptorelin ADT (36 months) over short-term (6 months) with radiotherapy in locally advanced prostate cancer.
  9. 2010-03-10
    FDA approves Trelstar 22.5 mg (6-month IM depot injection, NDA 022437) for advanced prostate cancer, providing the longest-acting US formulation.
  10. 2017-06-29
    FDA approves Triptodur (triptorelin 22.5 mg, 6-month extended-release IM injection, NDA 208956) for central precocious puberty in children aged 2 years and older. Developed by Debiopharm, marketed by Arbor Pharmaceuticals.
  11. 2020
    FDA publishes draft guidance on developing GnRH analogs for advanced prostate cancer, incorporating lessons from triptorelin and other GnRH agonist development programs.
  12. 2024
    Klotz and Tat publish a pooled post-hoc analysis of three triptorelin Phase III trials involving 592 patients, reporting an association between lower testosterone nadir and improved survival outcomes (PMID 38481666). Matveev et al. publish PRIORITI Phase IV trial results (PMID 38958195). Triptorelin marketed in over 80 countries worldwide.

Sources & FAQs

Research sources(19)

Frequently asked questions(5)

How does triptorelin differ from other GnRH agonists like leuprolide?

Triptorelin (Trelstar) and leuprolide (Lupron) are both GnRH agonists with the same fundamental mechanism — they downregulate pituitary GnRH receptors to suppress sex hormone production. The main differences are structural (triptorelin has a D-Trp substitution at position 6 vs D-Leu in leuprolide), pharmacokinetic (some studies suggest triptorelin may achieve deeper testosterone nadir levels), and practical (different formulation options and dosing schedules). Clinical trials comparing leuprolide and triptorelin head-to-head in CPP found no significant difference in efficacy or tolerability. Triptorelin's 6-month depot formulation of Trelstar offers longer dosing intervals. Both are considered first-line GnRH agonist options.

What is the tumor flare effect and how is it managed?

During the first 1-2 weeks of triptorelin treatment, the initial stimulation of pituitary GnRH receptors causes a transient surge in LH, FSH, and testosterone (in men) or estradiol (in women). In prostate cancer patients, this 'flare' can temporarily worsen symptoms including bone pain, urinary obstruction, and spinal cord compression, which can be a medical emergency in patients with vertebral metastases. The flare is managed by co-administering an antiandrogen (such as flutamide or bicalutamide) for the first 2-4 weeks of therapy to block the effects of the testosterone surge. GnRH antagonists (like degarelix) avoid the flare entirely but require more frequent dosing.

Can triptorelin be used for fertility treatment?

Yes. Outside the US, triptorelin (as Decapeptyl or Gonapeptyl) is widely used in IVF and assisted reproductive technology for pituitary downregulation — suppressing endogenous gonadotropin release to allow controlled ovarian stimulation. In the 'long' regimen, low-dose daily triptorelin is started in the mid-luteal phase and continued until ovarian stimulation with gonadotropins produces mature follicles. Studies show that low daily doses are sufficient to prevent a premature LH surge during IVF. Triptorelin can also trigger final oocyte maturation when used as a GnRH agonist trigger in antagonist regimens.

What are the long-term effects of triptorelin on bone health?

Long-term triptorelin use causes clinically significant bone mineral density (BMD) loss due to sustained sex hormone suppression. In prostate cancer patients on ADT, BMD can decrease by 2-5% per year, increasing fracture risk. Risk factors compounding this effect include older age, pre-existing osteopenia, family history of osteoporosis, and concurrent use of corticosteroids or anticonvulsants. Monitoring with periodic DEXA scans is recommended. Bone-protective agents (bisphosphonates like zoledronic acid, or denosumab) may be prescribed alongside long-term triptorelin therapy. Calcium, vitamin D supplementation, and weight-bearing exercise are standard supportive measures.

Is triptorelin used in gender-affirming care?

Yes. Triptorelin is used off-label (on-label in some European jurisdictions) as a puberty blocker for adolescents with gender dysphoria. By suppressing GnRH-driven puberty, it reversibly delays the development of secondary sexual characteristics, providing time for psychological assessment and decision-making before irreversible physical changes occur. A 2016 study (PMID 27318023) documented suppression of puberty-related hormones in 116 adolescents; it did not establish reductions in suicidality, depression, anxiety or body uneasiness. In adults, triptorelin is used as part of hormone therapy regimens — suppressing testosterone in transgender women (in conjunction with estradiol) or estrogen in transgender men (in conjunction with testosterone). The Endocrine Society and WPATH guidelines include GnRH agonists like triptorelin as a treatment option.